[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"app-context":3,"blog-who-owns-regeneron-pharmaceuticals-top-shareholders-and-recent-insider-trades-ES":222},{"languages":4,"categories":41,"products":125,"competitors":149},[5,9,13,17,21,25,29,33,37],{"name":6,"code":7,"id":8},"English","EN","TGFuZ3VhZ2U6ZW4=",{"name":10,"code":11,"id":12},"Español","ES","TGFuZ3VhZ2U6ZXM=",{"name":14,"code":15,"id":16},"Português","PT","TGFuZ3VhZ2U6cHQ=",{"name":18,"code":19,"id":20},"日本語","JA","TGFuZ3VhZ2U6amE=",{"name":22,"code":23,"id":24},"한국어","KO","TGFuZ3VhZ2U6a28=",{"name":26,"code":27,"id":28},"Deutsch","DE","TGFuZ3VhZ2U6ZGU=",{"name":30,"code":31,"id":32},"Italiano","IT","TGFuZ3VhZ2U6aXQ=",{"name":34,"code":35,"id":36},"Français","FR","TGFuZ3VhZ2U6ZnI=",{"name":38,"code":39,"id":40},"中文 (中国)","ZH","TGFuZ3VhZ2U6emg=",[42,73,104],{"icon":43,"slug":44,"title":45,"description":46,"featuredLinks":47},"mingcute:stock-line","stock-market-basics","Stock Market Basics","\u003Cp>Beginners' guides and practical tips for understanding stock market investing.\u003C\u002Fp>\n",[48,53,58,63,68],{"url":49,"title":50,"description":51,"ogImage":52},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-makes-stocks-go-up-and-down","What Makes Stocks Go Up and Down | TIKR.com","Understanding what makes stock prices go up and down can help investors better navigate investing. Click to learn more!","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-makes-stocks-go-up-and-down-banner\u002FWhat-makes-stocks-go-up-and-down-banner.jpg?_i=AA",{"url":54,"title":55,"description":56,"ogImage":57},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fdividend-yield-meaning-formula-example","Dividend Yield: Meaning, Formula, Example | Tikr.com Blog | TIKR.com","The dividend yield is a key metric for investors looking to gauge the income potential of their investments. It measures how much a company pays out in","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FDividend-yield\u002FDividend-yield.png?_i=AA",{"url":59,"title":60,"description":61,"ogImage":62},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fmarket-capitalization-definition-formula-and-why-it-matters","Market Capitalization: Definition, Formula, and Why It Matters | TIKR.com","Long-term investors often look at various valuation metrics when deciding whether to invest in a particular company. One helpful metric to evaluate is","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FMarket-Capitalization-Definition-Formula-and-Why-It-Matters\u002FMarket-Capitalization-Definition-Formula-and-Why-It-Matters.png?_i=AA",{"url":64,"title":65,"description":66,"ogImage":67},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fearnings-per-share-definition-formula-and-why-eps-matters","Earnings Per Share: Definition, Formula, and Why EPS Matters | TIKR.com","Earnings Per Share (EPS) represents the portion of a company's net earnings allocated to each share. Click to learn more!","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FEPS-Defiinition-formula-and-why-EPS-matters-1\u002FEPS-Defiinition-formula-and-why-EPS-matters-1.png?_i=AA",{"url":69,"title":70,"description":71,"ogImage":72},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-a-stock-price-target","What Is a Stock Price Target? | TIKR.com","A price target is a stock's estimated future price. It can help investors quickly find undervalued stocks. Learn more now!","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-a-Stock-Price-Target-2\u002FWhat-is-a-Stock-Price-Target-2.png?_i=AA",{"icon":74,"slug":75,"title":76,"description":77,"featuredLinks":78},"material-symbols:analytics-outline","fundamental-analysis","Fundamental Analysis","\u003Cp>In-depth resources and financial metrics to help you evaluate companies like a pro.\u003C\u002Fp>\n",[79,84,89,94,99],{"url":80,"title":81,"description":82,"ogImage":83},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fshare-repurchase-why-do-companies-buy-back-their-stock","Share Repurchase: Why Do Companies Buy Back Their Stock? | TIKR.com","Share repurchases, or share buybacks, have gained popularity in the last two decades. According to a report from Goldman Sachs, stock buybacks initiated","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FTIKR-BLOG-COVER-PHOTOS-3_544a7f4e\u002FTIKR-BLOG-COVER-PHOTOS-3_544a7f4e.png?_i=AA",{"url":85,"title":86,"description":87,"ogImage":88},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-a-good-return-on-invested-capital","What Is a Good Return on Invested Capital? | TIKR.com","Learning about Return on Invested Capital (ROIC) can help investors spot highly profitable stocks that can drive long-term returns. Learn more now!","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-a-good-return-on-Invested-capital\u002FWhat-is-a-good-return-on-Invested-capital.png?_i=AA",{"url":90,"title":91,"description":92,"ogImage":93},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-a-good-return-on-equity-ratio","What is a Good Return on Equity Ratio | Tikr.com Blog | TIKR.com","Return on Equity (ROE) is a financial ratio that reflects a company's profitability in relation to the equity invested by shareholders. It basically","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-a-good-return-on-equity-ratio-1\u002FWhat-is-a-good-return-on-equity-ratio-1.jpg?_i=AA",{"url":95,"title":96,"description":97,"ogImage":98},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-a-good-p-e-ratio","What Is a Good P\u002FE Ratio? | TIKR.com","Financial analysts and investors look at various metrics before deciding whether a stock is a buy. One of the metrics is the price-to-earnings ratio (P\u002FE","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-a-good-PE-ratio-1\u002FWhat-is-a-good-PE-ratio-1.jpg?_i=AA",{"url":100,"title":101,"description":102,"ogImage":103},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Ftop-6-metrics-for-investing-in-reits","Top 6 Metrics for Investing in REITs | TIKR.com","Real estate has been one of the greatest asset classes for wealth creation in history, and investing in Real Estate Investment Trusts (REITs) can allow","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FGroup-10\u002FGroup-10.png?_i=AA",{"icon":105,"slug":106,"title":107,"description":108,"featuredLinks":109},"hugeicons:investigation","investing-lingo","Investing Lingo","\u003Cp>A comprehensive glossary of investing terms and jargon so you can speak the language of the markets confidently.\u003C\u002Fp>\n",[110,115,120],{"url":111,"title":112,"description":113,"ogImage":114},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fenterprise-value-definition-and-calculation","Enterprise Value: Definition and Calculation | Tikr.com Blog | TIKR.com","Enterprise value (EV) is a financial metric that offers a comprehensive snapshot of a company's total value. Unlike market capitalization which solely","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FEnterprise-Value-Definition-and-Calculation_37576e40\u002FEnterprise-Value-Definition-and-Calculation_37576e40.png?_i=AA",{"url":116,"title":117,"description":118,"ogImage":119},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Febitda-definition-formula-how-to-use-it","EBITDA: Definition, Formula, How to Use It | TIKR.com","EBITDA stands for earnings before interest, taxes, depreciation and amortization. It's a financial metric commonly used to evaluate a company's financial","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FEBITDA-Definition-Formula-How-to-Use-It\u002FEBITDA-Definition-Formula-How-to-Use-It.png?_i=AA",{"url":121,"title":122,"description":123,"ogImage":124},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-the-free-cash-flow-formula-and-why-does-it-matter","What is the Free Cash Flow Formula and Why Does It Matter | TIKR.com","Free cash flow, or FCF, is the cash a company generates after it accounts for outflows required to maintain business operations and support capital","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-the-free-cash-flow-formula\u002FWhat-is-the-free-cash-flow-formula.png?_i=AA",[126,130,134,137,141,145],{"slug":127,"modified":128,"title":129},"valuation-model-builder","2025-07-03T00:18:53","Value Stocks Quickly and Accurately",{"slug":131,"modified":132,"title":133},"stock-portfolio-tracking","2024-12-02T22:21:28","Monitor Your Portfolio",{"slug":75,"modified":135,"title":136},"2025-01-21T22:10:52","Instantly Analyze Companies with In-Depth Metrics",{"slug":138,"modified":139,"title":140},"stock-screener","2024-12-02T22:13:31","Find the Best Stocks to Buy",{"slug":142,"modified":143,"title":144},"investor-stock-portfolio","2025-01-21T22:02:56","Follow Investment Moves of Top Investors",{"slug":146,"modified":147,"title":148},"analyze-stocks","2025-07-23T16:04:24","Analyze Stocks",[150,154,158,162,166,170,174,178,182,186,190,194,198,202,206,210,214,218],{"slug":151,"title":152,"modified":153},"bloomberg","Bloomberg","2025-01-16T14:23:44",{"slug":155,"title":156,"modified":157},"morningstar","Morningstar","2025-01-16T14:25:16",{"slug":159,"title":160,"modified":161},"sentieo","Sentieo","2025-01-16T17:58:27",{"slug":163,"title":164,"modified":165},"googlefinance","Google Finance","2025-01-17T19:39:37",{"slug":167,"title":168,"modified":169},"tradingview","TradingView","2025-01-16T18:17:01",{"slug":171,"title":172,"modified":173},"factset","Factset","2025-01-16T18:20:16",{"slug":175,"title":176,"modified":177},"finviz","Finviz","2025-01-16T18:23:40",{"slug":179,"title":180,"modified":181},"ycharts","YCharts","2025-01-16T18:32:19",{"slug":183,"title":184,"modified":185},"marketbeat","MarketBeat","2025-03-11T00:27:23",{"slug":187,"title":188,"modified":189},"benzinga","Benzinga","2025-03-11T00:31:00",{"slug":191,"title":192,"modified":193},"gurufocus","Gurufocus","2025-03-11T00:31:12",{"slug":195,"title":196,"modified":197},"fast-graphs","FAST Graphs","2025-03-11T00:31:19",{"slug":199,"title":200,"modified":201},"tipranks","TipRanks","2025-03-11T00:31:26",{"slug":203,"title":204,"modified":205},"seeking-alpha","Seeking Alpha","2025-03-11T00:31:45",{"slug":207,"title":208,"modified":209},"thestreet","TheStreet","2025-03-11T00:31:52",{"slug":211,"title":212,"modified":213},"investing-com","Investing.com","2025-03-11T00:32:00",{"slug":215,"title":216,"modified":217},"zacks","Zacks","2025-03-26T15:40:40",{"slug":219,"title":220,"modified":221},"alphasense","AlphaSense","2025-03-11T00:32:15",{"post":223,"seo":259,"relatedPosts":265,"suggestedPosts":341},{"id":224,"title":225,"date":226,"modified":227,"excerpt":228,"content":229,"wordCount":230,"lang":231,"uri":232,"slug":233,"cloudinaryAssetId":234,"featuredImageOriginalUrl":235,"featuredImageMetadata":236,"author":239,"editor":245,"categories":250,"relatedPosts":256,"seo":257},87721,"¿A quién pertenece Regeneron Pharmaceuticals? Principales accionistas y últimas operaciones con información privilegiada","2026-01-03T12:35:00","2026-01-03T11:17:06","\u003Cp>A continuación se indica quiénes tienen las mayores participaciones en Regeneron Pharmaceuticals en la actualidad y qué sugieren las recientes tendencias de propiedad y de información privilegiada sobre la confianza en el poder de los beneficios a largo plazo de la empresa y la solidez de su cartera de proyectos.\u003C\u002Fp>\n","\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fstock\u002Fabout?cid=33715&tid=2642551&ref=srk6m3\">\u003Cstrong>Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)\u003C\u002Fstrong>\u003C\u002Fa> es una empresa líder en biotecnología centrada en el desarrollo de medicamentos para enfermedades graves en las áreas de oftalmología, oncología e inmunología. Las acciones cotizaban recientemente en torno a \u003Cstrong> los 776 dólares por título\u003C\u002Fstrong>, lo que supone una capitalización bursátil de Regeneron de unos \u003Cstrong> 79.600 millones de dólares\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\n\n\u003Cp>Fundada y dirigida desde hace tiempo por \u003Cstrong>Leonard Schleifer\u003C\u002Fstrong>, Regeneron es ampliamente conocida por su modelo de investigación impulsado internamente y su enfoque disciplinado de la asignación de capital. Observar quién posee Regeneron y cómo operan las personas con información privilegiada ayuda a mostrar cómo las grandes instituciones y la dirección de la empresa pueden estar posicionándose en torno a las acciones en la actualidad.\u003C\u002Fp>\n\n\n\n\u003Cp>\u003Cstrong>\u003Cem>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\" target=\"_blank\" rel=\"noreferrer noopener\">Descubra cuánto podrían subir sus acciones favoritas utilizando el nuevo modelo de valoración de TIKR (es gratuito) >>>.\u003C\u002Fa>\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\u003Ch2 class=\"wp-block-heading\" id=\"h-who-are-regeneron-s-top-shareholders\">\u003Cstrong>\u003Cstrong>¿Quiénes son los principales accionistas de Regeneron?\u003C\u002Fstrong>\u003C\u002Fstrong>\u003C\u002Fh2>\n\n\n\n\u003Cfigure class=\"wp-block-image size-full\">\u003Cimg width=\"1477\" height=\"870\" data-public-id=\"images\u002FREGN-2_877257a191\u002FREGN-2_877257a191.webp\" loading=\"lazy\" decoding=\"async\" src=\"https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1477,h_870,c_scale\u002Ff_webp,q_auto\u002Fv1767438520\u002Fimages\u002FREGN-2_877257a191\u002FREGN-2_877257a191.webp?_i=AA\" alt=\"Regeneron Pharmaceuticals stock\" class=\"wp-post-87721 wp-image-87725\" data-format=\"webp\" data-transformations=\"f_webp,q_auto\" data-version=\"1767438520\" data-seo=\"1\" srcset=\"https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Ff_webp,q_auto\u002Fv1767438520\u002Fimages\u002FREGN-2_877257a191\u002FREGN-2_877257a191.webp?_i=AA 1477w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_300,h_177,c_scale\u002Ff_webp,q_auto\u002Fv1767438520\u002Fimages\u002FREGN-2_877257a191\u002FREGN-2_877257a191.webp?_i=AA 300w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1024,h_603,c_scale\u002Ff_webp,q_auto\u002Fv1767438520\u002Fimages\u002FREGN-2_877257a191\u002FREGN-2_877257a191.webp?_i=AA 1024w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_768,h_452,c_scale\u002Ff_webp,q_auto\u002Fv1767438520\u002Fimages\u002FREGN-2_877257a191\u002FREGN-2_877257a191.webp?_i=AA 768w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1200,h_707,c_scale\u002Ff_webp,q_auto\u002Fv1767438520\u002Fimages\u002FREGN-2_877257a191\u002FREGN-2_877257a191.webp?_i=AA 1200w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1400,h_825,c_scale\u002Ff_webp,q_auto\u002Fv1767438520\u002Fimages\u002FREGN-2_877257a191\u002FREGN-2_877257a191.webp?_i=AA 1400w\" sizes=\"auto, (max-width: 1477px) 100vw, 1477px\" \u002F>\u003Cfigcaption class=\"wp-element-caption\">Principales accionistas de Regeneron Pharmaceuticals\u003C\u002Ffigcaption>\u003C\u002Ffigure>\n\n\n\n\u003Cp>La base accionarial de Regeneron está encabezada por grandes inversores institucionales, muchos de los cuales tienden a mantenerse a lo largo de los ciclos del mercado. Los últimos registros muestran una mezcla de recortes y adiciones, lo que sugiere diferentes puntos de vista sobre la valoración y el crecimiento a largo plazo en lugar de una única narrativa dominante.\u003C\u002Fp>\n\n\n\n\u003Cul class=\"wp-block-list\">\n\u003Cli>\u003Cstrong>The Vanguard Group, Inc:\u003C\u002Fstrong> 8.995.042 acciones\u003Cstrong>(8,71%\u003C\u002Fstrong>), \u003Cstrong>~6.980 millones de dólares de valor\u003C\u002Fstrong>. Recorta 376.355 acciones\u003Cstrong>(-4,02%\u003C\u002Fstrong>).\u003C\u002Fli>\n\n\n\n\u003Cli>\u003Cstrong>BlackRock Institutional Trust Company, N.A.\u003C\u002Fstrong>: 5.461.663 acciones\u003Cstrong>(5,29%\u003C\u002Fstrong>), \u003Cstrong>~4.240 millones de dólares de valor\u003C\u002Fstrong>. Recorta 204.209 acciones\u003Cstrong>(-3,60%\u003C\u002Fstrong>).\u003C\u002Fli>\n\n\n\n\u003Cli>\u003Cstrong>State Street Investment Management (US)\u003C\u002Fstrong>: 4.691.223 acciones\u003Cstrong>(4,54%\u003C\u002Fstrong>), \u003Cstrong>~3.640 millones de dólares\u003C\u002Fstrong>. Recorte de 140.779 acciones\u003Cstrong>(-2,91%\u003C\u002Fstrong>).\u003C\u002Fli>\n\n\n\n\u003Cli>\u003Cstrong>Dodge & Cox\u003C\u002Fstrong>: 4.550.845 acciones\u003Cstrong>(4,41%\u003C\u002Fstrong>), \u003Cstrong>~3.530 millones de dólares\u003C\u002Fstrong>. Añadidas 724.562 acciones\u003Cstrong>(+18,94%\u003C\u002Fstrong>).\u003C\u002Fli>\n\n\n\n\u003Cli>\u003Cstrong>JP Morgan Asset Management\u003C\u002Fstrong>: 2.946.879 acciones\u003Cstrong>(2,85%\u003C\u002Fstrong>), \u003Cstrong>~2.290 millones de dólares\u003C\u002Fstrong>. Añadidas 130.726 acciones\u003Cstrong>(+4,64%\u003C\u002Fstrong>).\u003C\u002Fli>\n\n\n\n\u003Cli>\u003Cstrong>Geode Capital Management, LLC\u003C\u002Fstrong>: 2.535.898 acciones\u003Cstrong>(2,46%\u003C\u002Fstrong>), \u003Cstrong> valor de ~1.970 millones de dólares\u003C\u002Fstrong>. Añadidas 70.844 acciones\u003Cstrong>(+2,87%\u003C\u002Fstrong>).\u003C\u002Fli>\n\n\n\n\u003Cli>\u003Cstrong>Invesco Capital Management (QQQ Trust)\u003C\u002Fstrong>: 2.183.806 acciones\u003Cstrong>(2,11%\u003C\u002Fstrong>), \u003Cstrong>~$1,70B de valor\u003C\u002Fstrong>. Recorta 5.936 acciones\u003Cstrong>(-0,27%\u003C\u002Fstrong>).\u003C\u002Fli>\n\n\n\n\u003Cli>\u003Cstrong>Putnam Investment Management, LLC\u003C\u002Fstrong>: 2.147.962 acciones (\u003Cstrong>2,08%\u003C\u002Fstrong>), \u003Cstrong>~$1,67B de valor\u003C\u002Fstrong>. Añadió 117.427 acciones\u003Cstrong>(+5,78%\u003C\u002Fstrong>).\u003C\u002Fli>\n\n\n\n\u003Cli>\u003Cstrong>Capital World Investors\u003C\u002Fstrong>: 1.998.366 acciones\u003Cstrong>(1,93%\u003C\u002Fstrong>), \u003Cstrong> valor aproximado de 1.550 millones de dólares\u003C\u002Fstrong>. Añadidas 32.348 acciones\u003Cstrong>(+1,65%\u003C\u002Fstrong>).\u003C\u002Fli>\n\n\n\n\u003Cli>\u003Cstrong>Loomis, Sayles & Company, L.P.\u003C\u002Fstrong>: 1.979.453 acciones\u003Cstrong>(1,92%\u003C\u002Fstrong>), \u003Cstrong>~1.540 millones de dólares de valor\u003C\u002Fstrong>. Añadidas 38.383 acciones\u003Cstrong>(+1,98%\u003C\u002Fstrong>).\u003C\u002Fli>\n\n\n\n\u003Cli>\u003Cstrong>Fidelity Management & Research Company LLC\u003C\u002Fstrong>: 1.886.652 acciones\u003Cstrong>(1,83%\u003C\u002Fstrong>), \u003Cstrong>~1.460 millones de dólares de valor\u003C\u002Fstrong>. Recorta 1.375.220 acciones\u003Cstrong>(-42,16%\u003C\u002Fstrong>).\u003C\u002Fli>\n\u003C\u002Ful>\n\n\n\n\u003Cp>Para los inversores, esta combinación de propiedad pone de relieve el apoyo pasivo constante junto con gestores activos que ajustan la exposición en función de la valoración, las expectativas de crecimiento y la estrategia de la cartera.\u003C\u002Fp>\n\n\n\n\u003Ch3 class=\"wp-block-heading\" id=\"h-hedge-fund-highlights\">Lo más destacado de los hedge funds\u003C\u002Fh3>\n\n\n\n\u003Cp>Un movimiento notable fue el de \u003Cstrong>Dodge & Cox\u003C\u002Fstrong>, que aumentó significativamente su participación en \u003Cstrong>Regeneron Pharmaceuticals\u003C\u002Fstrong>, añadiendo más de \u003Cstrong>700.000 acciones\u003C\u002Fstrong> para elevar su posición a un \u003Cstrong> valor\u003C\u002Fstrong> aproximado de \u003Cstrong> 3.500 millones de dólares\u003C\u002Fstrong>. Este movimiento puede sugerir una creciente confianza en el perfil de beneficios a largo plazo de Regeneron bajo la dirección de su fundador \u003Cstrong>, Leonard Schleifer\u003C\u002Fstrong>, aun cuando el crecimiento a corto plazo siga siendo objeto de debate.\u003C\u002Fp>\n\n\n\n\u003Cp>\u003Cstrong>Renaissance Technologies\u003C\u002Fstrong>, fundada por \u003Cstrong>Jim Simons\u003C\u002Fstrong>, sigue manteniendo su exposición a Regeneron. Aunque la empresa ajusta posiciones con frecuencia, su presencia continua sugiere que Regeneron sigue siendo atractiva dentro de las estrategias cuantitativas a los niveles de precios actuales.\u003C\u002Fp>\n\n\n\n\u003Cp>\u003Cstrong>Balyasny Asset Management\u003C\u002Fstrong>, dirigida por \u003Cstrong>Dmitry Balyasny\u003C\u002Fstrong>, también parece mantener una posición significativa en Regeneron. La participación del fondo puede reflejar el interés de gestores multiestrategia que se posicionan en torno a la opcionalidad de la cartera y la durabilidad de los márgenes, más que en el impulso de los beneficios a corto plazo.\u003C\u002Fp>\n\n\n\n\u003Cp>\u003Cstrong>Gotham Asset Management\u003C\u002Fstrong>, fundado por \u003Cstrong>Joel Greenblatt\u003C\u002Fstrong>, sigue siendo otro tenedor notable. El hecho de que Gotham siga siendo accionista sugiere que Regeneron aún puede ser valorada favorablemente según criterios de valoración o calidad dentro de marcos disciplinados y basados en los fundamentales. Para los inversores, el posicionamiento de los hedge funds parece más selectivo que masivo.\u003C\u002Fp>\n\n\n\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\">\u003Cstrong>\u003Cem>Siga a los principales accionistas de más de 50.000 valores mundiales (es gratis) >>>\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\n\n\n\u003Ch2 class=\"wp-block-heading\" id=\"h-regeneron-s-recent-insider-trades\">\u003Cstrong>\u003Cstrong>Últimas operaciones de Regeneron con información privilegiada\u003C\u002Fstrong>\u003C\u002Fstrong>\u003C\u002Fh2>\n\n\n\n\u003Cfigure class=\"wp-block-image size-full\">\u003Cimg width=\"1472\" height=\"836\" data-public-id=\"images\u002FREGN-3_8772674549\u002FREGN-3_8772674549.webp\" loading=\"lazy\" decoding=\"async\" src=\"https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1472,h_836,c_scale\u002Ff_webp,q_auto\u002Fv1767438527\u002Fimages\u002FREGN-3_8772674549\u002FREGN-3_8772674549.webp?_i=AA\" alt=\"Regeneron Pharmaceuticals stock\" class=\"wp-post-87721 wp-image-87726\" data-format=\"webp\" data-transformations=\"f_webp,q_auto\" data-version=\"1767438527\" data-seo=\"1\" srcset=\"https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Ff_webp,q_auto\u002Fv1767438527\u002Fimages\u002FREGN-3_8772674549\u002FREGN-3_8772674549.webp?_i=AA 1472w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_300,h_170,c_scale\u002Ff_webp,q_auto\u002Fv1767438527\u002Fimages\u002FREGN-3_8772674549\u002FREGN-3_8772674549.webp?_i=AA 300w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1024,h_582,c_scale\u002Ff_webp,q_auto\u002Fv1767438527\u002Fimages\u002FREGN-3_8772674549\u002FREGN-3_8772674549.webp?_i=AA 1024w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_768,h_436,c_scale\u002Ff_webp,q_auto\u002Fv1767438527\u002Fimages\u002FREGN-3_8772674549\u002FREGN-3_8772674549.webp?_i=AA 768w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1200,h_682,c_scale\u002Ff_webp,q_auto\u002Fv1767438527\u002Fimages\u002FREGN-3_8772674549\u002FREGN-3_8772674549.webp?_i=AA 1200w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1400,h_795,c_scale\u002Ff_webp,q_auto\u002Fv1767438527\u002Fimages\u002FREGN-3_8772674549\u002FREGN-3_8772674549.webp?_i=AA 1400w\" sizes=\"auto, (max-width: 1472px) 100vw, 1472px\" \u002F>\u003Cfigcaption class=\"wp-element-caption\">Últimas operaciones con información privilegiada de Regeneron Pharmaceuticals\u003C\u002Ffigcaption>\u003C\u002Ffigure>\n\n\n\n\u003Cp>Los archivos de información privilegiada muestran un grupo de transacciones a principios de diciembre que implican a altos ejecutivos y directores, que generalmente representan pequeñas porciones de la propiedad global.\u003C\u002Fp>\n\n\n\n\u003Cul class=\"wp-block-list\">\n\u003Cli>\u003Cstrong>Leonard S. Schleifer (Funcionario y Director)\u003C\u002Fstrong>: Vendió 155.145 acciones a ~701 dólares; adquirió 172.723 acciones a ~556 dólares.\u003C\u002Fli>\n\n\n\n\u003Cli>\u003Cstrong>George D. Yancopoulos (directivo y consejero)\u003C\u002Fstrong>: Vendió 131.874 acciones a ~701 dólares; adquirió 146.815 acciones a ~556 dólares.\u003C\u002Fli>\n\n\n\n\u003Cli>\u003Cstrong>Daniel P. Van Plew (directivo)\u003C\u002Fstrong>: Vendió 4.458 acciones a ~$701 a ~$713; registró 3.715 acciones a $0.\u003C\u002Fli>\n\n\n\n\u003Cli>\u003Cstrong>Marion E. McCourt (directivo)\u003C\u002Fstrong>: Vendió 2.357 acciones a ~$701 a ~$713; registró 2.476 acciones a $0.\u003C\u002Fli>\n\n\n\n\u003Cli>\u003Cstrong>Andrew J. Murphy (directivo)\u003C\u002Fstrong>: Vendió 5.928 acciones entre ~701 y ~713 dólares; registró 3.715 acciones a 0 dólares.\u003C\u002Fli>\n\n\n\n\u003Cli>\u003Cstrong>Joseph J. LaRosa (directivo)\u003C\u002Fstrong>: Vendió 1.396 acciones a ~713 dólares; registró 2.476 acciones a 0 dólares.\u003C\u002Fli>\n\n\n\n\u003Cli>\u003Cstrong>Christopher R. Fenimore (directivo)\u003C\u002Fstrong>: Vendió 992 acciones a ~$713; registró 3.027 acciones a $0.\u003C\u002Fli>\n\n\n\n\u003Cli>\u003Cstrong>Jason Pitofsky (directivo)\u003C\u002Fstrong>: Vendió 989 acciones a ~$713.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\n\n\u003Cp>La mayoría de las transacciones representan menos \u003Cstrong>del 0,20%\u003C\u002Fstrong> de las acciones en circulación por persona. Algunos archivos incluyen acciones registradas a 0 $, que pueden estar relacionadas con adjudicaciones de acciones o con el calendario de compensaciones, aunque esto no está confirmado. Para los inversores, la actividad con información privilegiada parece comedida y no modifica sustancialmente la propiedad global.\u003C\u002Fp>\n\n\n\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\">\u003Cstrong>\u003Cem>Consulte los datos recientes sobre operaciones con información privilegiada de más de 50.000 valores de todo el mundo (es gratis) >>>\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\n\n\n\u003Ch2 class=\"wp-block-heading\" id=\"h-what-the-ownership-amp-insider-trade-data-tell-us\">Qué nos dicen los datos sobre propiedad y operaciones con información privilegiada\u003C\u002Fh2>\n\n\n\n\u003Cp>La base accionarial de Regeneron sigue anclada en las grandes instituciones, lo que proporciona estabilidad incluso cuando los gestores activos recortan o añaden posiciones. La actividad de los fondos de cobertura sugiere un interés selectivo más que una acumulación generalizada, lo que refleja el debate actual en torno a la valoración y la durabilidad del crecimiento a largo plazo.\u003C\u002Fp>\n\n\n\n\u003Cp>Las operaciones con información privilegiada parecen equilibradas, con ventas modestas y movimientos compensatorios de acciones que no modifican significativamente los niveles de propiedad. Para los inversores, los datos sugieren que Regeneron sigue considerándose una franquicia biotecnológica de alta calidad, pero el posicionamiento de instituciones y personas con información privilegiada apunta a un enfoque prudente y deliberado a los niveles de precios actuales.\u003C\u002Fp>\n\n\n\n\u003Ch2 class=\"wp-block-heading\" id=\"h-value-any-stock-in-under-60-seconds-it-s-free\">\u003Cstrong>\u003Cstrong>\u003Cstrong>Valore cualquier acción en menos de 60 segundos (es gratis)\u003C\u002Fstrong>\u003C\u002Fstrong>\u003C\u002Fstrong>\u003C\u002Fh2>\n\n\n\n\u003Cp>Con la \u003Cstrong>nueva herramienta Modelo de valoración\u003C\u002Fstrong> de TIKR, puede estimar el precio potencial de una acción en menos de un minuto.\u003C\u002Fp>\n\n\n\n\u003Cp>Todo lo que necesita son tres simples datos:\u003C\u002Fp>\n\n\n\n\u003Col class=\"wp-block-list\">\n\u003Cli>\u003Cem>Crecimiento de los ingresos\u003C\u002Fem>\u003C\u002Fli>\n\n\n\n\u003Cli>\u003Cem>Márgenes operativos\u003C\u002Fem>\u003C\u002Fli>\n\n\n\n\u003Cli>\u003Cem>Múltiplo PER de salida\u003C\u002Fem>\u003C\u002Fli>\n\u003C\u002Fol>\n\n\n\n\u003Cp>A partir de ahí, TIKR calcula el precio potencial de la acción y la rentabilidad total en los \u003Cstrong>escenarios\u003C\u002Fstrong> \u003Cstrong>alcista, bajista y básico\u003C\u002Fstrong>, para que pueda ver rápidamente si una acción parece \u003Cstrong>infravalorada o sobrevalorada\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\n\n\u003Cp>Si no está seguro de qué introducir, TIKR rellena automáticamente cada entrada utilizando las estimaciones de consenso de los analistas, ofreciéndole un punto de partida rápido y fiable.\u003C\u002Fp>\n\n\n\n\u003Cp>\u003Cstrong>\u003Cem>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\" target=\"_blank\" rel=\"noreferrer noopener\">Vea el valor real de una acción en menos de 60 segundos (gratis con TIKR) >>>\u003C\u002Fa>\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fp>\n",994,"es","\u002Fblog\u002Fwho-owns-regeneron-pharmaceuticals-top-shareholders-and-recent-insider-trades","who-owns-regeneron-pharmaceuticals-top-shareholders-and-recent-insider-trades","images\u002FRegeneron-Pharmaceuticals-stock-1\u002FRegeneron-Pharmaceuticals-stock-1","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1767438954\u002Fimages\u002FRegeneron-Pharmaceuticals-stock-1\u002FRegeneron-Pharmaceuticals-stock-1.png?_i=AA",{"altText":237,"imageCredit":238},"Who Owns Regeneron Pharmaceuticals? Top Shareholders and Recent Insider Trades","@Ivan S from Pexels via Canva",{"name":240,"slug":241,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":244},"Nikko Henson","nikkotikr","author","",[],{"name":246,"slug":247,"role":248,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":249},"Thomas Richmond","thomastikr","editor",[],[251],{"name":252,"slug":253,"uri":254,"description":243,"postsCount":255},"Reseñas de Acciones","reviews","\u002Fblog\u002Fcategory\u002Freviews",0,[],{"title":237,"metaDesc":258,"opengraphDescription":258,"twitterTitle":237,"twitterDescription":258},"Here’s who holds the biggest stakes in Regeneron Pharmaceuticals today and what recent ownership and insider trends suggest about confidence in the company’s long-term earnings power and pipeline strength.",{"title":237,"description":258,"twitterTitle":237,"twitterDescription":258,"author":240,"articlePublisher":260,"articlePublishedTime":226,"articleModifiedTime":227,"twitterLabel1":261,"twitterData1":262,"ogTitle":237,"ogDescription":258,"ogUrl":232,"ogImage":235,"ogImageWidth":263,"ogImageHeight":264,"ogImageSecureUrl":235,"ogImageAlt":237,"twitterImage":235},"TIKR.com","Tiempo de lectura estimado","7 minutes",1200,630,[266,281,296,311,326],{"id":255,"title":267,"date":268,"excerpt":269,"wordCount":270,"uri":271,"slug":272,"cloudinaryAssetId":273,"featuredImageOriginalUrl":274,"featuredImageMetadata":275,"author":276,"categories":278,"relatedPosts":280},"¿A quién pertenece Zimmer Biomet? Principales accionistas y últimas operaciones con información privilegiada","2026-01-03 12:05:00","A continuación se indica quiénes son los principales accionistas de Zimmer Biomet en la actualidad y qué sugieren las recientes tendencias de propiedad y de información privilegiada sobre la confianza en la demanda de procedimientos a largo plazo y las perspectivas de beneficios de la empresa.",816,"\u002Fblog\u002Fwho-owns-zimmer-biomet-holdings-top-shareholders-and-recent-insider-trades","who-owns-zimmer-biomet-holdings-top-shareholders-and-recent-insider-trades","images\u002FZimmer-Biomet-stock\u002FZimmer-Biomet-stock","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1767437498\u002Fimages\u002FZimmer-Biomet-stock\u002FZimmer-Biomet-stock.png?_i=AA",{"altText":267},{"name":240,"slug":241,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":277},[],[279],{"name":252,"slug":253,"uri":254,"description":243,"postsCount":255},[],{"id":255,"title":282,"date":283,"excerpt":284,"wordCount":285,"uri":286,"slug":287,"cloudinaryAssetId":288,"featuredImageOriginalUrl":289,"featuredImageMetadata":290,"author":291,"categories":293,"relatedPosts":295},"¿A quién pertenece Jazz Pharmaceuticals? Principales accionistas y últimas operaciones con información privilegiada","2026-01-02 22:23:40","A continuación, se muestra quiénes son los principales accionistas de Jazz Pharmaceuticals en la actualidad y qué sugieren los recientes cambios en la propiedad y la actividad de información privilegiada sobre la confianza en las perspectivas de beneficios a largo plazo de la empresa.",868,"\u002Fblog\u002Fwho-owns-jazz-pharmaceuticals-top-shareholders-and-recent-insider-trades","who-owns-jazz-pharmaceuticals-top-shareholders-and-recent-insider-trades","images\u002FJazz-Pharmaceuticals-stock-1\u002FJazz-Pharmaceuticals-stock-1","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1767392737\u002Fimages\u002FJazz-Pharmaceuticals-stock-1\u002FJazz-Pharmaceuticals-stock-1.png?_i=AA",{"altText":282},{"name":240,"slug":241,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":292},[],[294],{"name":252,"slug":253,"uri":254,"description":243,"postsCount":255},[],{"id":255,"title":297,"date":298,"excerpt":299,"wordCount":300,"uri":301,"slug":302,"cloudinaryAssetId":303,"featuredImageOriginalUrl":304,"featuredImageMetadata":305,"author":306,"categories":308,"relatedPosts":310},"¿A quién pertenece IQVIA Holdings? Principales accionistas y últimas operaciones con información privilegiada","2026-01-02 21:45:26","A continuación, se explica quién posee las mayores participaciones en IQVIA Holdings en la actualidad y qué sugieren los recientes cambios en la propiedad sobre la confianza en las perspectivas de crecimiento a largo plazo de la compañía.",925,"\u002Fblog\u002Fwho-owns-iqvia-holdings-top-shareholders-and-recent-insider-trades","who-owns-iqvia-holdings-top-shareholders-and-recent-insider-trades","images\u002FIQVIA-Holdings-stock\u002FIQVIA-Holdings-stock","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1767390039\u002Fimages\u002FIQVIA-Holdings-stock\u002FIQVIA-Holdings-stock.png?_i=AA",{"altText":297},{"name":240,"slug":241,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":307},[],[309],{"name":252,"slug":253,"uri":254,"description":243,"postsCount":255},[],{"id":255,"title":312,"date":313,"excerpt":314,"wordCount":315,"uri":316,"slug":317,"cloudinaryAssetId":318,"featuredImageOriginalUrl":319,"featuredImageMetadata":320,"author":321,"categories":323,"relatedPosts":325},"¿A quién pertenece Incyte Corporation? Principales accionistas y últimas operaciones con información privilegiada","2026-01-02 19:38:12","A continuación se muestra quién tiene las mayores participaciones en Incyte Corporation en la actualidad y qué sugieren los recientes cambios en la propiedad y la actividad de información privilegiada sobre la confianza en las perspectivas de beneficios y proyectos a largo plazo de la empresa.",893,"\u002Fblog\u002Fwho-owns-incyte-corporation-top-shareholders-and-recent-insider-trades","who-owns-incyte-corporation-top-shareholders-and-recent-insider-trades","images\u002FIncyte-stock\u002FIncyte-stock","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1767382563\u002Fimages\u002FIncyte-stock\u002FIncyte-stock.png?_i=AA",{"altText":312},{"name":240,"slug":241,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":322},[],[324],{"name":252,"slug":253,"uri":254,"description":243,"postsCount":255},[],{"id":255,"title":327,"date":328,"excerpt":329,"wordCount":330,"uri":331,"slug":332,"cloudinaryAssetId":333,"featuredImageOriginalUrl":334,"featuredImageMetadata":335,"author":336,"categories":338,"relatedPosts":340},"¿A quién pertenece Illumina? Principales accionistas y últimas operaciones con información privilegiada","2026-01-02 19:16:04","A continuación se indica quiénes poseen las mayores participaciones en Illumina en la actualidad y qué sugieren las recientes actividades de propiedad y de información privilegiada sobre la confianza en sus perspectivas de crecimiento a largo plazo.",875,"\u002Fblog\u002Fwho-owns-illumina-top-shareholders-and-recent-insider-trades","who-owns-illumina-top-shareholders-and-recent-insider-trades","images\u002FIllumina-stock_8770072baa\u002FIllumina-stock_8770072baa","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1767381316\u002Fimages\u002FIllumina-stock_8770072baa\u002FIllumina-stock_8770072baa.png?_i=AA",{"altText":327},{"name":240,"slug":241,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":337},[],[339],{"name":252,"slug":253,"uri":254,"description":243,"postsCount":255},[],[342,361,376,391,406,421,441,456,471,488],{"id":255,"title":343,"date":344,"excerpt":345,"wordCount":346,"uri":347,"slug":348,"cloudinaryAssetId":-1,"featuredImageOriginalUrl":349,"featuredImageMetadata":350,"author":351,"categories":355,"relatedPosts":360},"Por qué las acciones de Broadcom (AVGO) subieron un 50% en 2025","2026-01-02 14:45:00","Broadcom (AVGO), que ha caído un 15% desde sus máximos históricos, es un valor tecnológico de gran capitalización que ha devuelto un 50% a sus accionistas en 2025. ",656,"\u002Fblog\u002Fwhy-broadcom-nasdaq-avgo-stock-rose-50-in-2025","why-broadcom-nasdaq-avgo-stock-rose-50-in-2025","https:\u002F\u002Ftikr1.wpengine.com\u002Fwp-content\u002Fuploads\u002F2026\u002F01\u002FNEW-NOVEMBER-FEATURED-IMAGE-MAKER-15-8-600x400.png",{"altText":343},{"name":352,"slug":353,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":354},"Aditya Raghunath","adityatikr",[],[356],{"name":357,"slug":358,"uri":359,"description":243,"postsCount":255},"Inversión General","general-investing","\u002Fblog\u002Fcategory\u002Fgeneral-investing",[],{"id":255,"title":362,"date":363,"excerpt":364,"wordCount":365,"uri":366,"slug":367,"cloudinaryAssetId":368,"featuredImageOriginalUrl":369,"featuredImageMetadata":370,"author":371,"categories":373,"relatedPosts":375},"Por qué las acciones de Kratos Defense subieron un 190% en 2025","2026-01-02 14:15:00","Las acciones de Kratos Defense casi triplicaron el patrimonio de los inversores el año pasado, ya que la empresa de seguridad sigue ampliando su foso competitivo. ",1160,"\u002Fblog\u002Fwhy-kratos-defense-nasdaq-ktos-stock-surged-190-in-2025","why-kratos-defense-nasdaq-ktos-stock-surged-190-in-2025","images\u002FNEW-NOVEMBER-FEATURED-IMAGE-MAKER-15-7\u002FNEW-NOVEMBER-FEATURED-IMAGE-MAKER-15-7","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1767361825\u002Fimages\u002FNEW-NOVEMBER-FEATURED-IMAGE-MAKER-15-7\u002FNEW-NOVEMBER-FEATURED-IMAGE-MAKER-15-7.png?_i=AA",{"altText":362},{"name":352,"slug":353,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":372},[],[374],{"name":357,"slug":358,"uri":359,"description":243,"postsCount":255},[],{"id":255,"title":377,"date":378,"excerpt":379,"wordCount":380,"uri":381,"slug":382,"cloudinaryAssetId":383,"featuredImageOriginalUrl":384,"featuredImageMetadata":385,"author":386,"categories":388,"relatedPosts":390},"Por qué las acciones de Dollar Tree subieron un 64% en 2025","2026-01-02 13:45:00","Las acciones de Dollar Tree subieron un 64% en 2025, aplastando los rendimientos del mercado en general, ya que el minorista de descuento se centró en sus esfuerzos de reconversión. ",966,"\u002Fblog\u002Fwhy-dollar-tree-nasdaq-dltr-stock-rose-64-in-2025","why-dollar-tree-nasdaq-dltr-stock-rose-64-in-2025","images\u002FNEW-NOVEMBER-FEATURED-IMAGE-MAKER-15-5_8767165956\u002FNEW-NOVEMBER-FEATURED-IMAGE-MAKER-15-5_8767165956","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1767360245\u002Fimages\u002FNEW-NOVEMBER-FEATURED-IMAGE-MAKER-15-5_8767165956\u002FNEW-NOVEMBER-FEATURED-IMAGE-MAKER-15-5_8767165956.png?_i=AA",{"altText":377},{"name":352,"slug":353,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":387},[],[389],{"name":357,"slug":358,"uri":359,"description":243,"postsCount":255},[],{"id":255,"title":392,"date":393,"excerpt":394,"wordCount":395,"uri":396,"slug":397,"cloudinaryAssetId":398,"featuredImageOriginalUrl":399,"featuredImageMetadata":400,"author":401,"categories":403,"relatedPosts":405},"Por qué las acciones de Nebius subieron un 200% en 2025","2026-01-02 12:00:00","Las acciones de Nebius, que han caído un 40% desde sus máximos históricos, se han triplicado con creces en 2025 a medida que ganan terreno en el mercado de la inteligencia artificial, en rápida expansión. ",888,"\u002Fblog\u002Fwhy-nebius-nasdaq-nbis-stock-rose-200-in-2025","why-nebius-nasdaq-nbis-stock-rose-200-in-2025","images\u002FNEW-NOVEMBER-FEATURED-IMAGE-MAKER-15-3_87666ecc87\u002FNEW-NOVEMBER-FEATURED-IMAGE-MAKER-15-3_87666ecc87","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1767353835\u002Fimages\u002FNEW-NOVEMBER-FEATURED-IMAGE-MAKER-15-3_87666ecc87\u002FNEW-NOVEMBER-FEATURED-IMAGE-MAKER-15-3_87666ecc87.png?_i=AA",{"altText":392},{"name":352,"slug":353,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":402},[],[404],{"name":357,"slug":358,"uri":359,"description":243,"postsCount":255},[],{"id":255,"title":407,"date":408,"excerpt":409,"wordCount":410,"uri":411,"slug":412,"cloudinaryAssetId":413,"featuredImageOriginalUrl":414,"featuredImageMetadata":415,"author":416,"categories":418,"relatedPosts":420},"Por qué las acciones de Asana cayeron un 32% en 2025","2026-01-02 11:15:00","Con una caída de más del 90% desde sus máximos históricos, las acciones de Asana siguieron registrando un rendimiento inferior al de los mercados más amplios en 2025. ",731,"\u002Fblog\u002Fwhy-asana-stock-fell-32-in-2025","why-asana-stock-fell-32-in-2025","images\u002FNEW-NOVEMBER-FEATURED-IMAGE-MAKER-15_876606fa98\u002FNEW-NOVEMBER-FEATURED-IMAGE-MAKER-15_876606fa98","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1767351571\u002Fimages\u002FNEW-NOVEMBER-FEATURED-IMAGE-MAKER-15_876606fa98\u002FNEW-NOVEMBER-FEATURED-IMAGE-MAKER-15_876606fa98.png?_i=AA",{"altText":407},{"name":352,"slug":353,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":417},[],[419],{"name":357,"slug":358,"uri":359,"description":243,"postsCount":255},[],{"id":255,"title":422,"date":423,"excerpt":424,"wordCount":425,"uri":426,"slug":427,"cloudinaryAssetId":428,"featuredImageOriginalUrl":429,"featuredImageMetadata":430,"author":431,"categories":435,"relatedPosts":440},"CaixaBank acaba de alcanzar máximos históricos. Podrá seguir subiendo en 2026?","2025-12-31 15:15:00","A pesar de un repunte masivo, nuestro modelo muestra que las acciones de CABK podrían rendir alrededor de un 15% hasta 2030 a medida que su negocio de seguros se dispare.",987,"\u002Fblog\u002Fcaixabank-just-hit-all-time-highs-can-the-stock-keep-climbing-in-2026","caixabank-just-hit-all-time-highs-can-the-stock-keep-climbing-in-2026","images\u002F2_873969caee\u002F2_873969caee","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1767053079\u002Fimages\u002F2_873969caee\u002F2_873969caee.png?_i=AA",{"altText":422},{"name":432,"slug":433,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":434},"Wiltone Asuncion","wiltonetikr",[],[436],{"name":437,"slug":438,"uri":439,"description":243,"postsCount":255},"Valoración","valuation","\u002Fblog\u002Fcategory\u002Fvaluation",[],{"id":255,"title":442,"date":443,"excerpt":444,"wordCount":445,"uri":446,"slug":447,"cloudinaryAssetId":448,"featuredImageOriginalUrl":449,"featuredImageMetadata":450,"author":451,"categories":453,"relatedPosts":455},"Las acciones del Banco Bilbao Vizcaya Argentaria (BBVA) han subido un 110% este año, ¿todavía tienen recorrido?","2025-12-31 14:30:00","A pesar de unos márgenes operativos de primera clase, nuestro modelo prevé una rentabilidad anualizada del -1,2% para las acciones de BBVA en los próximos dos años.",1095,"\u002Fblog\u002Fup-110-this-year-does-banco-bilbao-vizcaya-argentaria-bbva-stock-still-have-room-to-run","up-110-this-year-does-banco-bilbao-vizcaya-argentaria-bbva-stock-still-have-room-to-run","images\u002FCopy-of-Random-Featured-Image-1-1\u002FCopy-of-Random-Featured-Image-1-1","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1766137070\u002Fimages\u002FCopy-of-Random-Featured-Image-1-1\u002FCopy-of-Random-Featured-Image-1-1.png?_i=AA",{"altText":442},{"name":432,"slug":433,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":452},[],[454],{"name":437,"slug":438,"uri":439,"description":243,"postsCount":255},[],{"id":255,"title":457,"date":458,"excerpt":459,"wordCount":460,"uri":461,"slug":462,"cloudinaryAssetId":463,"featuredImageOriginalUrl":464,"featuredImageMetadata":465,"author":466,"categories":468,"relatedPosts":470},"Las acciones del Banco de Sabadell han subido un 300% en los últimos 3 años, ¿podrán continuar su racha en 2026?","2025-12-30 16:15:00","Esta es la razón por la que las acciones de Banco Sabadell han subido un 87% desde sus mínimos de 52 semanas. Las acciones de Banco Sabadell podrían alcanzar su precio objetivo de 3,58 euros en 2029. ",1088,"\u002Fblog\u002Fup-300-over-the-past-3-years-can-banco-de-sabadell-stock-continue-its-run-in-2026","up-300-over-the-past-3-years-can-banco-de-sabadell-stock-continue-its-run-in-2026","images\u002FCopy-of-Random-Featured-Image-2\u002FCopy-of-Random-Featured-Image-2","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1766141023\u002Fimages\u002FCopy-of-Random-Featured-Image-2\u002FCopy-of-Random-Featured-Image-2.png?_i=AA",{"altText":457},{"name":432,"slug":433,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":467},[],[469],{"name":437,"slug":438,"uri":439,"description":243,"postsCount":255},[],{"id":255,"title":472,"date":473,"excerpt":474,"wordCount":475,"uri":476,"slug":477,"cloudinaryAssetId":478,"featuredImageOriginalUrl":479,"featuredImageMetadata":480,"author":481,"categories":485,"relatedPosts":487},"Por qué Netflix podría superar los 131 dólares por acción y alcanzar máximos históricos en 2026","2025-12-30 15:45:00","Netflix podría ofrecer una rentabilidad superior al 30% en 2027, ya que el crecimiento sostenido de los ingresos, la expansión de los márgenes y unas hipótesis de valoración estables respaldan una subida impulsada por los beneficios.",1212,"\u002Fblog\u002Fheres-why-netflix-could-pass-131-share-and-potentially-reach-all-time-highs-in-2026","heres-why-netflix-could-pass-131-share-and-potentially-reach-all-time-highs-in-2026","images\u002FFEATURED-IMAGE-MAKER-3_86684d6804\u002FFEATURED-IMAGE-MAKER-3_86684d6804","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_360,c_scale\u002Ff_webp,q_auto\u002Fv1765994506\u002Fimages\u002FFEATURED-IMAGE-MAKER-3_86684d6804\u002FFEATURED-IMAGE-MAKER-3_86684d6804.png?_i=AA",{"altText":472},{"name":482,"slug":483,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":484},"Gian Estrada","giantikr",[],[486],{"name":437,"slug":438,"uri":439,"description":243,"postsCount":255},[],{"id":255,"title":489,"date":490,"excerpt":491,"wordCount":492,"uri":493,"slug":494,"cloudinaryAssetId":495,"featuredImageOriginalUrl":496,"featuredImageMetadata":497,"author":498,"categories":500,"relatedPosts":502},"Por qué este valor de mediana capitalización podría subir un 100% en los próximos dos años","2025-12-30 12:30:00","dLocal es un valor de crecimiento de mediana capitalización que cotiza con una valoración atractiva dadas sus estimaciones estelares de ingresos y beneficios. ",1121,"\u002Fblog\u002Fwhy-this-mid-cap-nasdaq-dlo-stock-could-surge-100-over-the-next-two-years","why-this-mid-cap-nasdaq-dlo-stock-could-surge-100-over-the-next-two-years","images\u002FNEW-NOVEMBER-FEATURED-IMAGE-MAKER-15-1\u002FNEW-NOVEMBER-FEATURED-IMAGE-MAKER-15-1","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1767093096\u002Fimages\u002FNEW-NOVEMBER-FEATURED-IMAGE-MAKER-15-1\u002FNEW-NOVEMBER-FEATURED-IMAGE-MAKER-15-1.png?_i=AA",{"altText":489},{"name":352,"slug":353,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":499},[],[501],{"name":437,"slug":438,"uri":439,"description":243,"postsCount":255},[]]